Genetic testing

INTERACT COALITION FORMED TO ADVANCE PATIENT ACCESS TO GENETIC TESTING FOR HEREDITARY CANCER RISK

Retrieved on: 
Wednesday, April 3, 2024
Ovarian cancer, Quest Diagnostics, Gene, Mutation, Genetic testing, Chemoprophylaxis, Incidence, Risk, Genetics, Education, SAN, Patient, Policy, Cancer, Hereditary nonpolyposis colorectal cancer, Salpingo-oophorectomy, Mastectomy, Breast cancer, Therapy, BRCA2, Physician, BRCA1, Cancer syndrome, Human, Vaccine

The coalition seeks to provide a collective voice in support of the progression of medical professional and industry guidelines for genetic testing for inherited mutations that increase cancer risk.

Key Points: 
  • The coalition seeks to provide a collective voice in support of the progression of medical professional and industry guidelines for genetic testing for inherited mutations that increase cancer risk.
  • With growing insight into the role of genetic testing in cancer risk management and treatment, the population of individuals who benefit from knowing their genetic mutation status continues to increase.
  • Hereditary cancer genetic testing has been shown to improve outcomes by identifying those most at risk and informing management strategies.
  • Among the challenges to broadening access to genetic testing for hereditary cancer risk is a time lag in updating guidelines and medical policies after the publication of new medical literature.

Quest Diagnostics and Broad Clinical Labs to Evaluate Whole Genome Sequencing as First-Line Genetic Test for Developmental Delay

Retrieved on: 
Tuesday, April 2, 2024
Diagnosis, WGS, Disease, FACMG, Broad Institute, Genetic testing, Fragile X syndrome, Massachusetts General Hospital, MIT, Harvard University, CMA, Patient, Medical genetics, Research, Mortality, Laboratory, DGX, Senior, Genome, American College, Saliva, Intellectual disability, Hospital, Whole genome sequencing, ACMG, Blood, Quest Diagnostics, Antibiotics

SECAUCUS, N.J., April 2, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and Broad Clinical Labs, the world expert in whole genome sequencing (WGS), today announced a research collaboration designed to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders.

Key Points: 
  • "We are delighted to bring the experience and expertise of Broad Clinical Labs to this innovative collaboration with Quest.
  • "This type of collaboration between commercial laboratories and research institutions is vital to advance the field of genetic testing and increase utility and economic value."
  • While the ACMG recommends WGS for first-line genetic testing for intellectual disability and developmental delay, some providers continue to follow prior guidelines that recommend chromosomal microarray (CMA) as a first-line test.
  • Broad Clinical Labs is a leader in human whole genome sequencing, having sequenced over 600,000 genomes in service of its mission to accelerate the understanding and diagnosis of human disease.

Grant Cardone's Cardone Ventures Leads A Strategic Investment And Partnership With REVIV To Launch World's First Patented Precision Nutrition System With 10X Health

Retrieved on: 
Tuesday, April 2, 2024
Health, Conference, Health system, Genetic testing, Partnership, Genetics, CNE, Research, Daniel, Cardone, Therapy, Safety, Medical device

MIAMI, April 1, 2024 /PRNewswire-PRWeb/ -- Cardone Ventures is proud to announce its investment and partnership with the world's leading IV therapy company, REVIV Global, spearheaded by Sarah Lomas, with a decade-long commitment to safety, regulatory efficacy, and the life science aspects of IV Therapy.

Key Points: 
  • Grant Cardone and Cardone Ventures announce a strategic investment and partnership with REVIV Global to revolutionize nutritional health and launch the world's first patented Precision Nutrition System with its portfolio company 10X Health System.
  • Our patented Precision Nutrition technology will revolutionize the way that people worldwide will consume nutrition through supplements and IV Therapy via precision genetic-based algorithms.
  • Once you complete the 10X Precision Genetic test, a customer will be able to purchase 10X Precision Nutrition, 10X Precision Weight Management Supplements, and obtain a Precision IV at any REVIV or 10X location worldwide.
  • The partnership with Cardone Ventures and its portfolio company, 10X Health, will position 10X Health and REVIV as the dominant global players in precision wellness and nutrition.

The Prelude Network® Names Labcorp Its Preferred Genetic Carrier Screening Lab

Retrieved on: 
Friday, March 29, 2024
Genetic testing, Partnership, Physician, Patient, Fertility, Insurance, Inception, FDA, LH, Genetic counseling

HOUSTON, March 29, 2024 /PRNewswire/ -- The Prelude Network® (Prelude), the largest network of fertility clinics in North America, announced today an expansion of its partnership with Labcorp (NYSE: LH), a global leader of innovative diagnostic and biopharma laboratory services, to serve as its Preferred Genetic Carrier Screening Lab.

Key Points: 
  • The expansion of this partnership delivers another level of genetic carrier screening services to Prelude patients, including in-office phlebotomists and patient service centers.
  • Additionally, Labcorp offers comprehensive genetic counseling, services for provider questions, and complimentary review of carrier screening results for patients.
  • To improve financial access to genetic carrier screening for the U.S. patient population, Labcorp is contracted with many insurance companies.
  • "Prelude is excited to offer our patients greater access to best-in-class genetic carrier screening," says Lauri Black, Certified Genetic Counselor and Director of Genetic Services at Inception.

Personalized Nutrition Market Projected to Reach $38.22 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Friday, March 29, 2024
Standard, Health, Glanbia, Conditional sentence, Urbanization, Growth, Prevalence, Exercise, Nutrition, Genetic testing, Intelligence, Genome, App Store (iOS/iPadOS), Sleep, Amway, Diet, Ecosystem, Fonterra, Market, Bangladesh Technical Education Board, Feedback, Table

The global market for personalized nutrition is witnessing substantial growth, driven by a heightened focus on health and wellness, the advent of genetic testing, and a booming interest in nutrition.

Key Points: 
  • The global market for personalized nutrition is witnessing substantial growth, driven by a heightened focus on health and wellness, the advent of genetic testing, and a booming interest in nutrition.
  • The sector witnesses a favorable horizon with the digital shift toward online personalized nutrition services and the burgeoning startup ecosystem.
  • The key players in the Personalized Nutrition Market include Nestlé S.A., Herbalife Nutrition Ltd., Glanbia PLC, Fonterra Co-Operative Group Limited, Amway Corporation, and others.
  • "Dive into the Personalized Nutrition Market Landscape: Explore 181 Pages of Insights, 374 Tables, and 24 Figures"

Personalized Nutrition Market Projected to Reach $38.22 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Friday, March 29, 2024
Standard, Health, Glanbia, Conditional sentence, Urbanization, Growth, Prevalence, Exercise, Nutrition, Genetic testing, Intelligence, Genome, App Store (iOS/iPadOS), Sleep, Amway, Diet, Ecosystem, Fonterra, Market, Bangladesh Technical Education Board, Feedback, Table

The global market for personalized nutrition is witnessing substantial growth, driven by a heightened focus on health and wellness, the advent of genetic testing, and a booming interest in nutrition.

Key Points: 
  • The global market for personalized nutrition is witnessing substantial growth, driven by a heightened focus on health and wellness, the advent of genetic testing, and a booming interest in nutrition.
  • The sector witnesses a favorable horizon with the digital shift toward online personalized nutrition services and the burgeoning startup ecosystem.
  • The key players in the Personalized Nutrition Market include Nestlé S.A., Herbalife Nutrition Ltd., Glanbia PLC, Fonterra Co-Operative Group Limited, Amway Corporation, and others.
  • "Dive into the Personalized Nutrition Market Landscape: Explore 181 Pages of Insights, 374 Tables, and 24 Figures"

Bill Introduced in Minnesota Would Increase Access To Genetic Testing

Retrieved on: 
Thursday, March 28, 2024
Mutation, Genetic testing, Breast, Disease, Risk, Patient, Cancer, HF, Woman, Saliva, Breast cancer, Collection, Blood, Legislation

ST. PAUL, Minn., March 28, 2024 /PRNewswire/ -- Susan G. Komen®, the world's leading breast cancer organization, applauds Representative Patty Acomb (D-Minnetonka) for introducing legislation that would eliminate financial barriers to clinically appropriate genetic testing, as well as the recommended screenings based on the results of that testing.

Key Points: 
  • In Minnesota, more than 5,480 people will be diagnosed with breast cancer and 630 are expected to die of the disease in 2024 alone.
  • In the U.S., 5-10% of breast cancers are related to a known inherited gene mutation.
  • HF 5050 , introduced by Rep Acomb, eliminates the patient out-of-pocket costs for multi-gene panel testing for inherited gene mutations and evidence-based screenings, ensuring individuals have access to critical information regarding their lifetime cancer risk and recommended early detection and cancer surveillance.
  • Germline testing is a type of test that looks for inherited mutations that have been present in every cell of the body since birth.

Data-Science-Powered Research by Seattle Children's and Microsoft Shows Promise of Predicting SIDS and Other Causes of Sudden Death

Retrieved on: 
Thursday, March 28, 2024
Gene, Sudden death, Herbal cigarette, SIDS, Learning, Medical genetics, Child, Infant, Electronic cigarette, Oxygen, Rutgers University, Research institute, Microsoft, Partnership, Risk, International, Pediatrics, Death, Fatality, Seattle Children's, Preterm birth, Database, American Journal, Research, AI, University, Pregnancy, DRS, Cardiac arrest, Hypoxia, Genetic testing, Developing Story, Mortality, SUID, Doctor of Philosophy, Life, Smoking, Summit, Pacific Northwest, Medical device

The event was sponsored by The Center for Integrative Brain Research at Seattle Children's and Microsoft AI for Good Lab.

Key Points: 
  • The event was sponsored by The Center for Integrative Brain Research at Seattle Children's and Microsoft AI for Good Lab.
  • Among the many topics attendees discussed was groundbreaking new research that suggests genetic testing at birth may hold the promise of detecting SIDS risk — and potentially other causes of sudden death later in life.
  • The Aaron Matthew SIDS Research Foundation funds the database, which is maintained and managed at Seattle Children's Research Institute.
  • "Scientific research sometimes leads to surprises," said Jan-Marino Ramirez , PhD, Director of the Center for Integrative Brain Research at Seattle Children's.

Nucleus Genomics launches to bring whole-genome sequencing to the public

Retrieved on: 
Monday, March 25, 2024
Human Genome Project, WGS, Blood pressure, Genomics, Health, Certification, Informatics, Founders Fund, Genetic testing, Risk, Genetics, Human, PRS, DNA, Accreditation, Breast, CAP, Overalls, Facial muscles, Cancer, CLIA, Breast cancer, BRCA2, BMI, BRCA1

NEW YORK, March 25, 2024 /PRNewswire/ -- Nucleus Genomics, the next-generation genetic testing and analysis company, today announced the launch of its DNA analysis product to bring the benefits of personalized medicine to everyone.

Key Points: 
  • Nucleus further personalizes these risk assessments by integrating personal and lifestyle factors into their analysis — such as age, cholesterol levels, blood pressure, and BMI.
  • Nucleus will also offer pre-orders for its premium clinical-grade whole-genome sequencing (WGS) service, in which a customer's entire set of DNA will be read and analyzed.
  • Nucleus is proud to sequence all customer samples in the U.S. on Illumina's NovaSeq X Plus, the sequencing company's newest and most innovative high-throughput sequencing instrument.
  • Working with Illumina, Nucleus is leveraging this latest sequencing technology to make WGS broadly accessible to power personalized healthcare.

SOPHiA GENETICS Announces First Homologous Recombination Deficiency (HRD) Customer in Canada

Retrieved on: 
Wednesday, March 20, 2024
Ovarian cancer, Gene, Mutation, BRCA, Genetic testing, Patient, NGS, Research, DNA, Guideline, AI, University, Cancer, Hope, Quality of life, GENETICS, Oncology, Medicine, Clinical trial, Sophia Genetics, HRD, HRR, Pharmaceutical industry

BOSTON and ROLLE, Switzerland, March 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced the University of Saskatchewan (USask) as its first HRD customer in Canada. USask will implement the SOPHiA DDM™ Platform for use in its cutting-edge clinical trial, which aims to substantially improve the quality of life for ovarian cancer patients through expanded genetic testing. This is the first clinical trial in Canada designed to improve ovarian cancer treatment decisions and inspire guideline changes to increase access to advanced testing.

Key Points: 
  • BOSTON and ROLLE, Switzerland, March 20, 2024 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced the University of Saskatchewan (USask) as its first HRD customer in Canada.
  • This is the first clinical trial in Canada designed to improve ovarian cancer treatment decisions and inspire guideline changes to increase access to advanced testing.
  • It's exactly what we at SOPHiA GENETICS are working so hard to make available to clinician researchers around the world," said John Carey, Managing Director, NORAM, SOPHiA GENETICS.
  • The SOPHiA DDM™ Comprehensive Profiling Solution coupled with SOPHiA GENETICS' proprietary deep learning algorithm, GIInger™, will provide USask with a widespread look at potential mutations for each patient.